IN VITRO CYTOTOXICITY ACTIVITY AND IN VIVO ORAL TOXICITY OF Euphorbia hirta

KWAN YUET PING

UNIVERSITI SAJS MALAYSIA
2014
IN VITRO CYTOTOXICITY ACTIVITY AND IN VIVO ORAL TOXICITY OF Euphorbia hirta

by

KWAN YUET PING

Thesis submitted in fulfillment of the requirements for the degree of Doctor of Philosophy

AUGUST 2014
ACKNOWLEDGEMENTS

I wish to express my heartfelt gratitude to everyone who had helped me and made my pursuit for the PhD degree a pleasant and fulfilling experience. First and foremost, I would like to attribute my deepest gratitude to my supervisor, Dr. Sasidharan Sreenivasan, for giving me the opportunity to learn and work under his supervision. I would like to extend my appreciation for his expert guidance, advice and encouragement, without of which my PhD project would not have been so fruitful. Besides, my heartfelt thanks go to my co-supervisor Prof. Darah Ibrahim and field-supervisor Prof. Umi Kalsom binti Yusuf for giving me invaluable advice and encouragement throughout the duration of my study.

I would like to forward my appreciation to the laboratory staffs Mrs. Norhalida, Mrs. Dyana and Mrs. Fatihah from Institute for Research in Molecular Medicine (INFORMM) for their technical help and support in using cell culture and microscope facilities. I am thankful to Dr. Faisal and Mrs. Nor Fadhilah from Advanced Medical & Dental Institute (AMDI), for their technical help and assistance in using flow cytometer. I am very grateful to Dr. Lim Sheh Hong, Mr. Shanmugam, Mr. Soma, Mr. Letchimanan, Mrs. Shantini, Mr. Hamzah and Mr. Johari in School of Biological Sciences, for their guidance and kind help in the process of laboratory works. I would also like to thank Dr. Isma and Mr. Yusof for their kind support during the animal studies in Animal Research and Service Centre (ARASC). I am also grateful to the financial support of a research scholarship from the Ministry of Higher Education, Malaysia. To my fellow colleagues, Jothy, Kavitha, Vijaya, Grace, Boon Ping, Mooi Kwai, Wee Yee, Priscilla and Soo Ai, thank you for all the support...
and patience you have shown me through the years. Your encouragement and help made my PhD journey a much sweeter one.

Last but not least, I would like to thank my mother and sister for their endless love, faith and support. Thank you for always believing in me and encouraging me to go a little further, dream a little bigger. Special thanks go to Sean for being my pillar of support and for being there with me always, through the high and lows of my PhD journey. May all individuals mentioned above be blessed with constant love, health and happiness.

Kwan Yuet Ping

Institute for Research in Molecular Medicine

Universiti Sains Malaysia

August 2014
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>ii</td>
</tr>
<tr>
<td>TABLE OF CONTENTS</td>
<td>iv</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>xii</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>xxiii</td>
</tr>
<tr>
<td>LIST OF ABBREVIATIONS</td>
<td>xxv</td>
</tr>
<tr>
<td>ABSTRAK</td>
<td>xxvi</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>xxx</td>
</tr>
</tbody>
</table>

## CHAPTER 1.0: INTRODUCTION

1.1 Overview and rationale of the study  
1.2 Research objectives

## CHAPTER 2.0: LITERATURE REVIEW

2.1 Pharmaceuticals from plants  
   2.1.1 Background of herbal medicine in Malaysia  
   2.1.2 Safety concern on the use of pharmaceutical from plants  
2.2 *Euphorbia*  
   2.2.1 *Euphorbia hirta* L.  
      2.2.1.1 Botanical description  
      2.2.1.2 Origin and geographical distribution  
      2.2.1.3 Phytochemistry  
      2.2.1.4 Pharmacological activities
CHAPTER 3.0: CHROMATOGRAPHIC AND SPECTRAL FINGERPRINTING STANDARDIZATION OF Euphorbia hirta

3.1 Introduction

3.2 Materials and methods

3.2.1 Chemicals and reagents

3.2.2 Plant sample collection

3.2.3 Plant material extraction

3.2.4 Qualitative investigation

3.2.5 Fourier Transform Infrared (FTIR) fingerprinting

3.2.6 Gas chromatography-mass spectrometry (GC-MS) analysis

3.2.7 Heavy metal analysis

3.2.8 DPPH free radical scavenging assay

3.3 Statistical analysis

3.4 Results

3.4.1 Extraction

3.4.2 Herbarium of E. hirta

3.4.3 Qualitative investigation of E. hirta plant parts

3.4.4 FTIR analysis

3.4.5 GC-MS analysis

3.4.6 Heavy metal analysis

3.4.7 DPPH assay

3.5 Discussion

3.6 Conclusion
CHAPTER 4.0: IN VITRO CYTOTOXICITY OF E. hirta

4.1 Introduction

4.2 Materials and methods

4.2.1 Chemicals and reagents

4.2.2 Cell culture

4.2.2.1 Cell culture media

4.2.2.1.1 Dulbecco’s Modifies Eagle’s Medium (DMEM)

4.2.2.1.2 Roswell Park Memorial Institute Medium 1640 (RPMI)

4.2.2.2 Cell lines

4.2.3 Resuscitation of frozen cells

4.2.4 Subculturing of cells

4.2.5 Cell quantification

4.2.6 Brine shrimp lethality assay

4.2.7 MTT cytotoxicity assay

4.2.8 Morphological detection of apoptosis using light microscopy

4.2.9 Lactate Dehydrogenase (LDH) leakage assay

4.2.10 Annexin V/PI for apoptosis detection

4.2.11 DNA fragmentation

4.2.12 Morphological detection of apoptosis using Acridine Orange/Propidium Iodide (AO/PI) staining

4.2.13 Cell cycle analysis by flow cytometry

4.2.14 Reactive Oxygen Species (ROS) assay

4.2.15 Detection of caspase activity by colorimetric assay

4.2.16 Bradford protein assay
CHAPTER 5.0: GENOTOXICITY OF E. hirta

5.1 Introduction

5.2 Materials and methods

5.2.1 Cell lines

5.2.2 Chemicals and reagents

5.2.3 Allium cepa assay

5.2.3.1 Pre treatment

5.2.3.2 Slides preparation

5.2.3.3 Observation of specimen
5.2.4 Comet assay

5.3 Statistical analysis

5.4 Results

5.4.1 Effect of E. hirta extract on mitotic index (MI)

5.4.2 Effect of E. hirta extract on chromosome aberrations

5.4.3 Effect of E. hirta extract on micronuclei

5.4.4 Comet assay

5.5 Discussion

5.6 Conclusion

CHAPTER 6.0: IN VIVO TOXICITY TESTING OF E. hirta

6.1 Introduction

6.2 Materials and methods

6.2.1 Preparation of plant extract

6.2.2 Animals

6.2.3 Acute oral toxicity study

6.2.4 Sub-chronic toxicity study

6.2.5 Relative organ weight

6.2.6 Blood analyses

6.2.7 Histopathological analyses

6.3 Statistical analysis

6.4 Results

6.4.1 Effect of acute oral administration of E. hirta on the general behaviour in rats

6.4.2 Effect of acute oral administration of E. hirta on body weight in rats
6.4.3 Effect of acute oral administration of *E. hirta* on haematological indices in rats 176
6.4.4 Effect of acute oral administration of *E. hirta* on biochemical indices in rats 178
6.4.5 Effect of acute oral administration of *E. hirta* on organ weight in rats 180
6.4.6 Effect of acute oral administration of *E. hirta* on histological assessment of organs in rats 182
6.4.7 Effect of sub-chronic oral administration of *E. hirta* on the general behaviour in rats 143
6.4.8 Effect of sub-chronic oral administration of *E. hirta* on body weight in rats 195
6.4.9 Effect of sub-chronic oral administration of *E. hirta* on haematological indices in rats 198
6.4.10 Effect of sub-chronic oral administration of *E. hirta* on biochemical indices in rats 201
6.4.11 Effect of sub-chronic oral administration of *E. hirta* on organ weight in rats 204
6.4.12 Effect of sub-chronic oral administration of *E. hirta* on histological assessment of organs in rats 206

6.5 Discussion 232

6.6 Conclusion 240

**CHAPTER 7.0: FRACTIONATION AND IDENTIFICATION OF CYTOTOXIC FRACTION FROM *E. hirta*** 241

7.1 Introduction 241

7.2 Materials and methods 242

7.2.1 Preparation of plant extract 242

7.2.2 Fractionation and isolation of cytotoxic fraction from *E. hirta* 242

7.2.2.1 Solvent partitioning method 242

7.2.2.2 Medium Pressure Liquid Chromatography (MPLC) 242
7.2.2.3 Liquid Chromatography-Mass Spectrometry (LC-MS) 243

7.2.2.4 MTT cytotoxicity assay 244

7.3 Results 246

7.3.1 Fractionation of methanol extract of *E. hirta* 246
7.3.2 Cytotoxic effects of the subfractions on MCF-7 cells 246
7.3.3 Isolation and identification of compounds 253

7.4 Discussion 256

7.5 Conclusion 259

**CHAPTER 8.0: SUMMARY** 260

8.1 General conclusion 260

8.2 Suggestions for future studies 264

**REFERENCES** 265

**APPENDICES** 289

**LIST OF PUBLICATIONS** 311
## LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 2.1</td>
<td>Taxonomic classification of <em>E. hirta</em></td>
<td>10</td>
</tr>
<tr>
<td>Figure 2.2</td>
<td><em>Euphorbia hirta</em> plant</td>
<td>11</td>
</tr>
<tr>
<td>Figure 2.3</td>
<td><em>E. hirta</em> plant (1: plant habit; 2: young cyathium; 3: mature cyathium; 4: seed)</td>
<td>12</td>
</tr>
<tr>
<td>Figure 2.4</td>
<td>Chemical structure of some known compounds found in <em>E. hirta</em></td>
<td>14</td>
</tr>
<tr>
<td>Figure 2.5</td>
<td>Types of cell death</td>
<td>22</td>
</tr>
<tr>
<td>Figure 2.6</td>
<td>Cell cycle and DNA damage checkpoint</td>
<td>28</td>
</tr>
<tr>
<td>Figure 3.1</td>
<td>The herbarium voucher of <em>Euphorbia hirta</em></td>
<td>47</td>
</tr>
<tr>
<td>Figure 3.2</td>
<td>Microscopy of <em>E. hirta</em> leaf transverse section</td>
<td>50</td>
</tr>
<tr>
<td>Figure 3.3</td>
<td>Microscopy of <em>E. hirta</em> root transverse section</td>
<td>51</td>
</tr>
<tr>
<td>Figure 3.4</td>
<td>Microscopy of <em>E. hirta</em> stem transverse section</td>
<td>52</td>
</tr>
<tr>
<td>Figure 3.5</td>
<td>FTIR spectrum of methanolic extract of <em>E. hirta</em></td>
<td>54</td>
</tr>
<tr>
<td>Figure 3.6</td>
<td>GC-MS profile of 1,3,4,5-tetrahydroxycyclohexanecarboxylic acid at retention time 11.7</td>
<td>57</td>
</tr>
<tr>
<td>Figure 3.7</td>
<td>Calibration curve of 1,3,4,5-tetrahydroxycyclohexanecarboxylic acid by GC-MS</td>
<td>58</td>
</tr>
<tr>
<td>Figure 4.1</td>
<td>Haemacytometer chamber grid pattern showing four squares to be used to count viable cells</td>
<td>80</td>
</tr>
<tr>
<td>Figure 4.2</td>
<td>Haemacytometer chamber grid pattern showing viable cells</td>
<td>80</td>
</tr>
<tr>
<td>Figure 4.3</td>
<td>Toxic effects of the <em>E. hirta</em> extract after 24 h using brine shrimp lethality assay</td>
<td>92</td>
</tr>
</tbody>
</table>
Figure 4.4  Toxic effects of potassium dichromate after 24 h using brine shrimp lethality assay
Figure 4.5  Cell viability curve of Vero cells treated with *E. hirta* extract by using MTT assay
Figure 4.6  Cell viability curve of MCF-7 cells treated with *E. hirta* extract by using MTT assay
Figure 4.7  Cell viability curve of HeLa cells treated with *E. hirta* extract by using MTT assay
Figure 4.8  Cell viability curve of HT-29 cells treated with *E. hirta* extract by using MTT assay
Figure 4.9  Cell viability curve of Vero cells treated with doxorubicin hydrochloride by using MTT assay
Figure 4.10 Cell viability curve of MCF-7 cells treated with doxorubicin hydrochloride by using MTT assay
Figure 4.11 Cell viability curve of HeLa cells treated with doxorubicin hydrochloride by using MTT assay
Figure 4.12 Cell viability curve of HT-29 cells treated with doxorubicin hydrochloride by using MTT assay
Figure 4.13 Morphological changes of MCF-7 cells treated with 0.5% (v/v) DMSO as negative control, viewed under an inverted light microscope
Figure 4.14 Morphological changes of MCF-7 cells treated with IC$_{50}$ of *E. hirta* extract for 24 h, viewed under an inverted light microscope
Figure 4.15 Morphological changes of MCF-7 cells treated with IC$_{50}$ of *E. hirta* extract for 48 h, viewed under an inverted light microscope
Figure 4.16 Morphological changes of MCF-7 cells treated with IC$_{50}$ of *E. hirta* extract for 72 h, viewed under an inverted light microscope
Figure 4.17 Morphological changes of MCF-7 cells treated with IC$_{50}$ of doxorubicin hydrochloride for 24 h, viewed under an inverted light microscope
Figure 4.18  Morphological changes of MCF-7 cells treated with IC$_{50}$ of doxorubicin hydrochloride for 48 h, viewed under an inverted light microscope

Figure 4.19  Morphological changes of MCF-7 cells treated with IC$_{50}$ of doxorubicin hydrochloride for 72 h, viewed under an inverted light microscope

Figure 4.20  The influence of *E. hirta* extract on the membrane integrity of MCF-7 cells after 24 h of treatment

Figure 4.21  AO/PI staining of MCF-7 cells treated with 0.5% (v/v) DMSO as negative control, viewed under a fluorescence microscope

Figure 4.22  AO/PI staining of MCF-7 cells treated with IC$_{50}$ of *E. hirta* extract for 24 h, viewed under a fluorescence microscope

Figure 4.23  AO/PI staining of MCF-7 cells treated with IC$_{50}$ of *E. hirta* extract for 48 h, viewed under a fluorescence microscope

Figure 4.24  AO/PI staining of MCF-7 cells treated with IC$_{50}$ of *E. hirta* extract for 72 h, viewed under a fluorescence microscope

Figure 4.25  Assessment of frequencies of viable, apoptotic and necrotic cells in *E. hirta* extract (25 g/mL) treated MCF-7 cancer cells at various incubation times

Figure 4.26  Annexin V/PI double-staining assay of MCF-7 cells treated with *E. hirta* extract (25 g/mL)

Figure 4.27  Annexin V/PI double-staining assay of MCF-7 cells treated with *E. hirta* extract (50 g/mL)

Figure 4.28  DNA fragmentations in MCF-7 cells were treated for 24 h with indicated concentrations of *E. hirta*.

Figure 4.29  Cell cycle distribution of the cells upon *E. hirta* treatment

Figure 4.30  Effect of *E. hirta* on cell cycle distribution of MCF-7 cells after 24 hour of treatment.

Figure 4.31  Effect of *E. hirta* extract on intracellular ROS

xv
production by MCF-7 cells

Figure 4.32 Measurement of ROS with DCFH-DA in MCF-7 cells treated with H\textsubscript{2}O\textsubscript{2} and \textit{E. hirta} at various concentrations with increasing incubation time

Figure 4.33 A standard curve of protein concentration using Bradford method

Figure 4.34 Caspases activity in MCF-7 cells was analyzed using caspase colorimetric protease assay kit

Figure 5.1 Effect of \textit{E. hirta} extract and ethyl methanesulfonate on mitotic index

Figure 5.2 Effect of \textit{E. hirta} extract and ethyl methanesulfonate on micronuclei

Figure 5.3 \textit{A. cepa} root tips without treatment showing normal prophase

Figure 5.4 \textit{A. cepa} root tips treated with \textit{E. hirta} extract showing C-mitosis

Figure 5.5 \textit{A. cepa} root tips without treatment showing normal metaphase

Figure 5.6 \textit{A. cepa} root tips treated with \textit{E. hirta} extract showing sticky chromosome

Figure 5.7 \textit{A. cepa} root tips without treatment showing normal anaphase

Figure 5.8 \textit{A. cepa} root tips treated with \textit{E. hirta} extract showing chromosome bridge

Figure 5.9 \textit{A. cepa} root tips without treatment showing normal telophase

Figure 5.10 \textit{A. cepa} root tips treated with \textit{E. hirta} extract showing vagrant chromosome

Figure 5.11 \textit{A. cepa} root tips without treatment showing normal interphase
Figure 5.12  A. cepa root tips treated with E. hirta extract showing micronuclei

Figure 5.13  Photomicrographs of stained DNA of untreated MCF-7 cells showing no DNA damage

Figure 5.14  Photomicrographs of stained DNA of MCF-7 cells treated with 25 μg/mL E. hirta for 24 h showing DNA damage in comet tail

Figure 5.15  Effect of E. hirta and doxorubicin on tail moment using Comet assay DNA damage in MCF-7 cells

Figure 6.1  Flow chart for acute toxicity study in accordance to OECD guideline 420 (OECD, 2001a)

Figure 6.2  Flow chart for subchronic toxicity study in accordance to OECD guideline 408 (OECD, 1998)

Figure 6.3  2-3 rats of same sex were placed in the cages

Figure 6.4  Mean body weight of male rats in acute toxicity study

Figure 6.5  Mean body weight of female rats in acute toxicity study

Figure 6.6  Photomicrograph showing section of heart of male control rats in acute toxicity study

Figure 6.7  Photomicrograph showing section of heart of male rats treated with 5000 mg/kg/day of E. hirta extract in acute toxicity study

Figure 6.8  Photomicrograph showing section of heart of female control rats in acute toxicity study

Figure 6.9  Photomicrograph showing section of heart of female rats treated with 5000 mg/kg/day of E. hirta extract in acute toxicity study

Figure 6.10  Photomicrograph showing section of lung of male control rats in acute toxicity study
Figure 6.11  Photomicrograph showing section of lung of male rats treated with 5000 mg/kg/day of *E. hirta* extract in acute toxicity study

Figure 6.12  Photomicrograph showing section of lung of female control rats in acute toxicity study

Figure 6.13  Photomicrograph showing section of lung of female rats treated with 5000 mg/kg/day of *E. hirta* extract in acute toxicity study

Figure 6.14  Photomicrograph showing section of kidney of male control rats in acute toxicity study

Figure 6.15  Photomicrograph showing section of kidney of male rats treated with 5000 mg/kg/day of *E. hirta* extract in acute toxicity study

Figure 6.16  Photomicrograph showing section of kidney of female control rats in acute toxicity study

Figure 6.17  Photomicrograph showing section of kidney of female rats treated with 5000 mg/kg/day of *E. hirta* extract in acute toxicity study

Figure 6.18  Photomicrograph showing section of liver of male control rats in acute toxicity study

Figure 6.19  Photomicrograph showing section of liver of male rats treated with 5000 mg/kg/day of *E. hirta* extract in acute toxicity study

Figure 6.20  Photomicrograph showing section of liver of female control rats in acute toxicity study

Figure 6.21  Photomicrograph showing section of liver of female rats treated with 5000 mg/kg/day of *E. hirta* extract in acute toxicity study

Figure 6.22  Photomicrograph showing section of spleen of male control rats in acute toxicity study

Figure 6.23  Photomicrograph showing section of spleen of male rats treated with 5000 mg/kg/day of *E. hirta* extract in acute toxicity study
| Figure 6.24 | Photomicrograph showing section of spleen of female control rats in acute toxicity study | 192 |
| Figure 6.25 | Photomicrograph showing section of spleen of male rats treated with 5000 mg/kg/day of *E. hirta* extract in acute toxicity study | 192 |
| Figure 6.26 | Mean body weight of male rats in sub-chronic toxicity study | 196 |
| Figure 6.27 | Mean body weight of female rats in sub-chronic toxicity study | 196 |
| Figure 6.28 | Mean body weight of rats in satellite group in sub-chronic toxicity study | 197 |
| Figure 6.29 | Photomicrograph showing section of heart of male control rats in sub-chronic toxicity study | 207 |
| Figure 6.30 | Photomicrograph showing section of heart of male rats treated with 50 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study | 207 |
| Figure 6.31 | Photomicrograph showing section of heart of male rats treated with 250 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study | 208 |
| Figure 6.32 | Photomicrograph showing section of heart of male rats treated with 1000 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study | 208 |
| Figure 6.33 | Photomicrograph showing section of heart of male rats as the satellite group in sub-chronic toxicity study | 209 |
| Figure 6.34 | Photomicrograph showing section of heart of female control rats in sub-chronic toxicity study | 209 |
| Figure 6.35 | Photomicrograph showing section of heart of female rats treated with 50 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study | 210 |
| Figure 6.36 | Photomicrograph showing section of heart of female rats treated with 250 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study | 210 |
| Figure 6.37 | Photomicrograph showing section of heart of female rats treated with 1000 mg/kg/day of *E. hirta* extract in | 211 |
sub-chronic toxicity study

Figure 6.38 Photomicrograph showing section of heart of female rats as the satellite group in sub-chronic toxicity study 211

Figure 6.39 Photomicrograph showing section of lung of male control rats in sub-chronic toxicity study 212

Figure 6.40 Photomicrograph showing section of lung of male rats treated with 50 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study 212

Figure 6.41 Photomicrograph showing section of lung of male rats treated with 250 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study 213

Figure 6.42 Photomicrograph showing section of lung of male rats treated with 1000 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study 213

Figure 6.43 Photomicrograph showing section of lung of male rats as the satellite group in sub-chronic toxicity study 214

Figure 6.44 Photomicrograph showing section of lung of female control rats in sub-chronic toxicity study 214

Figure 6.45 Photomicrograph showing section of lung of female rats treated with 50 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study 215

Figure 6.46 Photomicrograph showing section of lung of female rats treated with 250 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study 215

Figure 6.47 Photomicrograph showing section of lung of female rats treated with 1000 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study 216

Figure 6.48 Photomicrograph showing section of lung of female rats as the satellite group in sub-chronic toxicity study 216

Figure 6.49 Photomicrograph showing section of kidney of male control rats in sub-chronic toxicity study 217

Figure 6.50 Photomicrograph showing section of kidney of male rats treated with 50 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study 217
| Figure 6.51 | Photomicrograph showing section of kidney of male rats treated with 250 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study |
| Figure 6.52 | Photomicrograph showing section of kidney of male rats treated with 1000 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study |
| Figure 6.53 | Photomicrograph showing section of kidney of male rats as the satellite group in sub-chronic toxicity study |
| Figure 6.54 | Photomicrograph showing section of kidney of female control rats in sub-chronic toxicity study |
| Figure 6.55 | Photomicrograph showing section of kidney of female rats treated with 50 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study |
| Figure 6.56 | Photomicrograph showing section of kidney of female rats treated with 250 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study |
| Figure 6.57 | Photomicrograph showing section of kidney of female rats treated with 1000 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study |
| Figure 6.58 | Photomicrograph showing section of kidney of male rats as the satellite group in sub-chronic toxicity study |
| Figure 6.59 | Photomicrograph showing section of liver of male control rats in sub-chronic toxicity study |
| Figure 6.60 | Photomicrograph showing section of liver of male rats treated with 50 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study |
| Figure 6.61 | Photomicrograph showing section of liver of male rats treated with 250 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study |
| Figure 6.62 | Photomicrograph showing section of liver of male rats treated with 1000 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study |
| Figure 6.63 | Photomicrograph showing section of liver of male rats as the satellite group in sub-chronic toxicity study |
Figure 6.64 Photomicrograph showing section of liver of female control rats in sub-chronic toxicity study

Figure 6.65 Photomicrograph showing section of liver of female rats treated with 50 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study

Figure 6.66 Photomicrograph showing section of liver of female rats treated with 250 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study

Figure 6.67 Photomicrograph showing section of liver of female rats treated with 1000 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study

Figure 6.68 Photomicrograph showing section of liver of female rats as the satellite group in sub-chronic toxicity study

Figure 6.69 Photomicrograph showing section of spleen of male control rats in sub-chronic toxicity study

Figure 6.70 Photomicrograph showing section of spleen of male rats treated with 50 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study

Figure 6.71 Photomicrograph showing section of spleen of male rats treated with 250 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study

Figure 6.72 Photomicrograph showing section of spleen of male rats treated with 1000 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study

Figure 6.73 Photomicrograph showing section of spleen of male rats as the satellite group in sub-chronic toxicity study

Figure 6.74 Photomicrograph showing section of spleen of female control rats in sub-chronic toxicity study

Figure 6.75 Photomicrograph showing section of spleen of female rats treated with 50 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study

Figure 6.76 Photomicrograph showing section of spleen of female rats treated with 250 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study
Figure 6.77 Photomicrograph showing section of spleen of female rats treated with 1000 mg/kg/day of *E. hirta* extract in sub-chronic toxicity study

Figure 6.78 Photomicrograph showing section of spleen of female rats as the satellite group in sub-chronic toxicity study

Figure 7.1 Flow chart for fractionation of *E. hirta* methanol extract

Figure 7.2 Cell viability curve of MCF-7 cells treated with *E. hirta* hexane fraction by using MTT assay

Figure 7.3 Cell viability curve of MCF-7 cells treated with *E. hirta* EH Hex 4 subfraction by using MTT assay

Figure 7.4 Cell viability curve of MCF-7 cells treated with *E. hirta* EH Hex 7 subfraction by using MTT assay

Figure 7.5 Cell viability curve of MCF-7 cells treated with *E. hirta* EH EtOAc 1 subfraction by using MTT assay

Figure 7.6 Cell viability curve of MCF-7 cells treated with *E. hirta* EH EtOAc 6 subfraction by using MTT assay

Figure 7.7 Cell viability curve of MCF-7 cells treated with *E. hirta* EH EtOAc 7 subfraction by using MTT assay

Figure 7.8 Cell viability curve of MCF-7 cells treated with *E. hirta* EH EtOAc 8 subfraction by using MTT assay

Figure 7.9 Cell viability curve of MCF-7 cells treated with *E. hirta* EH BuOH 8 subfraction by using MTT assay

Figure 7.10 Cell viability curve of MCF-7 cells treated with *E. hirta* EH BuOH 9 subfraction by using MTT assay

Figure 7.11 LC chromatogram of *E. hirta* EH Hex 4 subfraction

Figure 7.12 ESI total ion chromatogram of *E. hirta* hexane extract

Figure 7.13 MS spectra for *E. hirta* EH Hex 4 subfraction

Figure 7.14 3,3’,4’,5,7-Pentahydroxy-8-(5-oxo-2-pyrrolidinyl)flavone isolated from the *E. hirta*
# LIST OF TABLES

| Table 3.1 | The main compounds identified in methanol extract of *E. hirta* crude extract | 56 |
| Table 3.2 | Biological activity of major phyto-components identified in *E. hirta* crude extract by GC-MS | 56 |
| Table 3.3 | Heavy metal concentration in *E. hirta* extract | 60 |
| Table 3.4 | DPPH antioxidant activity of 1 mg/mL *E. hirta* extract within duration of 3 months | 62 |
| Table 4.1 | Types of cell lines used on the *in vitro* screening and their complete growth medium requirements | 77 |
| Table 4.2 | Cytotoxic effects of methanol extract of *E. hirta* on several cancer cells and normal cells at their respective IC<sub>50</sub> | 95 |
| Table 4.3 | Cytotoxic effects of doxorubicin hydrochloride on several cancer cells and normal cells at their respective IC<sub>50</sub> | 95 |
| Table 5.1 | Mitotic index in control and *E. hirta* treatment concentrations on *A. cepa* root cells | 142 |
| Table 5.2 | Chromosomal aberrations in control and *E. hirta* treatment concentrations on *A. cepa* root cells | 144 |
| Table 5.3 | Micronuclei in control and *E. hirta* treatment concentrations on *A. cepa* root cells | 146 |
| Table 5.4 | Mean percentage of DNA damage by the comet assay in MCF-7 cells treated with *E. hirta* and doxorubicin hydrochloride | 154 |
| Table 6.1 | Cage side observations on general appearance and behavioural observations for control and treated groups | 173 |
| Table 6.2 | Haematology values of rats treated with single dose of *E. hirta* methanol extract in acute oral toxicity study | 177 |
| Table 6.3 | Biochemistry values of rats treated with single dose of *Euphorbia hirta* methanol extract in acute oral toxicity study |
| Table 6.4 | Relative organ weights of rats treated with single dose of *E. hirta* methanol extract in acute oral toxicity study |
| Table 6.5 | Cage side observations on general appearance and behavioural observations for control and treated groups |
| Table 6.6 | Haematological values of male rats treated with daily dose of *E. hirta* methanol extract in sub-chronic toxicity study |
| Table 6.7 | Haematological values of male rats treated with daily dose of *E. hirta* methanol extract in sub-chronic toxicity study |
| Table 6.8 | Biochemical values of male rats treated with daily dose of *E. hirta* methanol extract in sub-chronic toxicity study |
| Table 6.9 | Biochemical values of female rats treated with daily dose of *E. hirta* methanol extract in sub-chronic toxicity study |
| Table 6.10 | Relative organ weights of rats treated with daily dose of *E. hirta* methanol extract in sub-chronic toxicity study |
| Table 7.1 | IC\textsubscript{50} values of *E. hirta* extract various isolated fractions towards MCF-7 at 24 hour as determined by using MTT assay |
### LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAS</td>
<td>Atomic Absorption Spectroscopy</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine aminotransferase</td>
</tr>
<tr>
<td>ANOVA</td>
<td>Analysis of variance</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate aminotransferase</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine triphosphate</td>
</tr>
<tr>
<td>DCFH-DA</td>
<td>2’, 7’-Dichlorodihydrofluorescin diacetate</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s Modified Eagle’s Medium</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl Sulfoxide</td>
</tr>
<tr>
<td>E. hirta</td>
<td>Euphorbia hirta</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>FBS</td>
<td>Fetal Bovine Serum</td>
</tr>
<tr>
<td>FITC</td>
<td>Fluorescein isothiocyanate</td>
</tr>
<tr>
<td>FTIR</td>
<td>Fourier Transform Infrared</td>
</tr>
<tr>
<td>GC-MS</td>
<td>Gas Chromatography-Mass Spectrometry</td>
</tr>
<tr>
<td>HPLC</td>
<td>High Performance Liquid Chromatography</td>
</tr>
<tr>
<td>IC&lt;sub&gt;50&lt;/sub&gt;</td>
<td>Inhibitory Concentration 50%</td>
</tr>
<tr>
<td>LC-MS</td>
<td>Liquid Chromatography-Mass Spectrometry</td>
</tr>
<tr>
<td>LD&lt;sub&gt;50&lt;/sub&gt;</td>
<td>Lethal Dose 50%</td>
</tr>
<tr>
<td>MPLC</td>
<td>Medium Pressure Liquid Chromatography</td>
</tr>
<tr>
<td>MTT</td>
<td>3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</td>
</tr>
<tr>
<td>NOAEL</td>
<td>No Observed Adverse Effect Level</td>
</tr>
<tr>
<td>OECD</td>
<td>Organisation for Economic Cooperation and Development</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate Buffered Saline</td>
</tr>
<tr>
<td>PI</td>
<td>Propidium Iodide</td>
</tr>
<tr>
<td>RPMI 1640</td>
<td>Roswell Park Memorial Institute</td>
</tr>
<tr>
<td>RNAse</td>
<td>Ribonuclease</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive Oxygen Species</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard Error of the Mean</td>
</tr>
<tr>
<td>SPSS</td>
<td>Statistical Package for the Social Sciences</td>
</tr>
<tr>
<td>WBC</td>
<td>White Blood Cell count</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organisation</td>
</tr>
</tbody>
</table>
AKTIVITI SITOTOKSIKAN SECARA IN VITRO DAN UJIAN KETOKSIKAN ORAL SECARA IN VIVO DARIPADA *Euphorbia hirta*

ABSTRAK

*Euphorbia hirta* adalah sejenis tumbuhan yang digunakan dalam perubatan tradisional secara meluas untuk mengubati pelbagai jenis penyakit. Sitotoksik, genotoksik secara *in vitro* dan penilaian ketoksikan secara *in vivo* ekstrak metanol daripada *E. hirta* telah diselidik dalam kajian ini. Penilaian pelbagai parameter farmakognosi telah dijalankan mengikut garis panduan Pertubuhan Kesihatan Sedunia (WHO) untuk pempiawaian ekstrak *E. hirta*. Pempiawaian kandungan kimia melibatkan kuantifikasi sebatian kimia utama dalam ekstrak *E. hirta*. Kaedah GC-MS yang telah digunakan untuk kuantifikasi asid 1,3,4,5 tetrahidroksisikloheksanakarbosilik dalam ekstrak adalah cepat, tepat, dan linear. Enam puncak utama dalam lingkungan 600 - 1500 dan 2800 - 3400 cm\(^{-1}\) diperhatikan dalam spektrum FTIR. Kepekatan logam berat dalam ekstrak *E. hirta* adalah didapati berada di bawah had yang dibenarkan. Dalam asai antioksidan terhadap radikal bebas DPPH, ekstrak *E. hirta* menunjukkan aktiviti antioksidan 50% ke atas, tidak bergantung pada masa pengekstrakan. Kajian potensi ketoksikan ekstrak *E. hirta* telah dilakukan dengan menggunakan kaedah kematian anak udang dan ujian sitotoksisiti terhadap sel-sel kanser. Ekstrak *E. hirta* menunjukkan kesan toksik yang ketara terhadap anak udang dengan nilai (kepekatan maut) LC\(_{50}\) sebanyak 620.38 µg/mL (24 jam). Perbandingan keputusan ini dengan kesan toksik kawalan positif iaitu kalium dikromat didapati bahawa kesan aktiviti ketoksikan yang ditunjukkan oleh ekstrak metanol adalah sederhana. Ujian sitotoksisiti MTT

Untuk mengenal pasti sebatian kimia yang bersifat sitotoksiti, penyisihan ekstrak *E. hirta* telah dilakukan berpandukan bioasai. Subfraksi heksan *E. hirta* iaitu EH Hex 4 menunjukkan aktiviti sitotoksiti yang signifikan di kalangan semua fraksi yang diuji. Analisis selanjutnya dengan menggunakan kaedah LC-MS terhadap fraksi EH Hex 4 membawa kepada identifikasi sebatian 3,3’·4’,5,7-Pentahydroxy-8-(5-oxo-2-pyrroolidinyl) flavone sebagai agen cenderung kepada sitotoksik di dalam ekstrak *E. hirta*. Data yang diperolehi daripada kajian ini menunjukkan bahawa *E. hirta* menyebabkan kematian sel secara apoptotik dan mencadangkan bahawa *E. hirta* boleh digunakan sebagai agen anti-kanser yang mengaruhi apoptosis untuk rawatan kanser payudara dengan kajian lanjutan yang terperinci. Kesan potensi genotoksik
E. hirta telah dikaji dengan menggunakan ujian Allium cepa dan asai komet. Dalam ujian A. cepa, ekstrak E. hirta menunjukkan kesan genotoksik dan mitodepresif yang signifikan pada kepekatan sebanyak 1000 µg/mL. Peningkatan dalam nilai aberasi kromosom yang bersandarkan kepada kepekatan ekstrak telah diperhatikan seperti kromosom kelekitan, kromosom c-mitosis, kromosom jambatan dan kromosom vagrant. Sel mikronukleus juga telah diperhatikan pada interfasa. Dalam ujian komet, rawatan dengan 25 µg/mL ekstrak E. hirta selama 72 jam pada sel-sel MCF-7 menyebabkan peningkatan kerosakan DNA sebanyak 48.16% berbanding dengan kawalan yang tidak dirawat. Data ini mengesahkan kesan genotoksik ekstrak E. hirta.

Ujian ketoksikan oral akut dan sub-kronik ekstrak E. hirta telah dilakukan dengan menggunakan tikus Sprague Dawley. Ekstrak pada dos tunggal iaitu sebanyak 5000 mg/kg berat badan tidak menunjukkan kematian atau kesan toksik yang berkaitan dengan rawatan tersebut dalam tempoh pemerhatian selama 14 hari. Oleh itu, dos LD₅₀ (dos membunuh) tumbuhan ini dianggarkan melebihi 5000 mg/kg. Dalam kajian ketoksikan sub-kronik, pemberian ekstrak E. hirta sebanyak 50 mg/kg, 250 mg/kg, 1000 mg/kg/hari berat badan menunjukkan tiada sebarang perbezaan yang signifikan dalam makanan dan penggunaan air, perubahan berat badan, parameter hematologi dan biokimia, berat relatif organ dan pemerhatian secara kasar berbanding dengan kumpulan kawalan. Pemeriksaan makropatologi dan histopatologi kesemua organ tidak menunjukkan sebarang perubahan morfologi. Penganalisaan keputusan ini bersama-sama dengan informasi mengenai tanda-tanda penyakit, tingkah laku dan pemantauan kesihatan boleh membawa kepada kesimpulan bahawa pengambilan jangka panjang ekstrak E. hirta selama 90 hari tidak menyebabkan ketoksikan sub-kronik. Kesimpulannya, keputusan ujian ketoksikan secara in vitro dan in vivo yang diperolehi dalam kajian ini membuktikan
tentang kepentingan kedua-dua kaedah tersebut untuk memperolehi data penilaian toksikologi yang komprehensif untuk agen terapeutik semula jadi.
IN VITRO CYTOTOXICITY ACTIVITY AND IN VIVO ACUTE ORAL TOXICITY OF Euphorbia hirta

ABSTRACT

Euphorbia hirta is an annual plant that has been widely used in traditional medicine to treat various diseases. In vitro cytotoxicity, genotoxicity properties and in vivo toxicological evaluation of E. hirta methanol extract were investigated in this study. Various pharmacognostical parameters evaluation was carried out as per World Health Organization (WHO) guidelines procedure for the standardization of E. hirta extract. The chemical constituent aspect of standardization involves quantification of the main chemical components in E. hirta. The GC-MS analysis was used for quantification of 1,3,4,5-tetrahydroxycyclohexanecarboxylic acid in the extract was rapid, accurate and linear. Six major peaks in the range of 600 - 1500 and 2800 - 3400 cm$^{-1}$ were observed in the FTIR spectra. The concentrations of heavy metals determined in E. hirta extract were well below the permissible limit. In 2,2-Diphenyl-1-picrylhydrazyl radical (DPPH) assay, the extract showed a general consistency on antioxidant activity above 50%, independent of the extraction time. The potential cytotoxicity effect of E. hirta was investigated using brine shrimp lethality assay and the cytotoxicity assay against cancer cells. The extract of E. hirta showed significant toxicity against brine shrimp with (Lethal Concentration) LC$_{50}$ value of 620.38µg/mL (24 h). Comparison with positive control potassium dichromate signifies that cytotoxicity exhibited by the methanol extract have moderate activity. The 3-(4, 5-dimethyl thiazol-2yl)-2, 5-diphenyltetrazolium bromide (MTT) cytotoxicity assay showed that E. hirta inhibited MCF-7 cell xxx
viability with the (Inhibitory Concentration) IC₅₀ values 25.26 µg/ml in a dose and time-dependent manner. Microscopic studies showed that E. hirta treated cells exhibited marked morphological features characteristic of apoptosis. E. hirta extract also had an ignorable influence on the lactate dehydrogenase (LDH) leakage and generating intracellular reactive oxygen species (ROS). Therefore, E. hirta might induce the cytotoxicity via a ROS-independent mechanism in MCF-7 cells. The Annexin V/Propidium Iodide flow cytometry study confirmed that E. hirta extract induced apoptosis in MCF-7 cells. E. hirta extract treatment also resulted in DNA fragmentation in MCF-7 cells. Moreover, E. hirta treatment resulted in the accumulation of cells at the S and G₂/M phases as well as apoptosis. The caspase activity study revealed that E. hirta extract induced apoptosis through the caspase-3 independent pathway by the activation of caspase-2, 6, 8 and 9. To identify the cytotoxic compound, E. hirta extract was subjected to bioassay-guided fractionation. E. hirta hexane subfraction, namely EH Hex 4 demonstrated highest activity among all the fractions tested. Further Liquid Chromatography–Mass Spectrometry (LC-MS) analysis of EH Hex 4 led to identification of 3,3’,4’,5,7-Pentahydroxy-8-(5-oxo-2-pyrrolidinyl) flavone as the likely cytotoxic agent in E. hirta extract. The data obtained from this study revealed that E. hirta induced apoptotic cell death and suggests that E. hirta could be used as an apoptosis-inducing anti-cancer agent for breast cancer treatment with further detailed studies. The potential genotoxic effect of E. hirta was investigated using Allium cepa and comet assay. In A. cepa assay, the result showed that the methanol extract of E. hirta exerted significant genotoxic and mitodepressive effects at 1000 µg/mL. A dose-dependent increase of chromosome aberrations was also observed such as stickiness, c-mitosis, bridges and vagrant chromosomes. Micronucleated cells were also observed at interphase. In the comet
assay, the treatment of 25 µg/mL of *E. hirta* extract for 72 h on MCF-7 cells caused an increase in DNA damage by approximately 48.16% compared to the unchallenged control which confirmed the genotoxic effect of *E. hirta* extract. The acute and sub-chronic oral toxicity of *E. hirta* was evaluated in Sprague Dawley rats. The extract at a single dose of 5000 mg/kg did not produce treatment related signs of toxicity or mortality in the animals tested during the 14-day observation period. Therefore, the (Lethal Dose) LD$_{50}$ of this plant was estimated to be more than 5000 mg/kg. In the subchronic toxicity study, the administration of 50 mg/kg, 250 mg/kg, 1000 mg/kg/day of *E. hirta* extract per body weight revealed no significant difference in the body weight change, haematological and biochemical parameters, relative organ weights and gross findings compared to the control group. Macropathology and histopathology examination of all organs did not reveal morphological alteration. Analyses of these results with the information of signs, behaviour and health monitoring could lead to the conclusion that the long-term oral administration of *E. hirta* extract for 90 days does not cause toxicity. In conclusion, *in vitro* and *in vivo* toxicity results obtained in this study proved the importance of both methods to obtain comprehensive toxicological evaluation of natural product agents.
CHAPTER 1.0: INTRODUCTION

1.1 Overview and rationale of the study

Natural products, especially medicinal plants, have played a significant role in drug discovery and development of therapeutic agents. Plants contain many biologically active compound(s) which have potential for development as therapeutic agents. More than 35,000 plant species have been reported to be used in various human cultures around the world for medical purposes (Lewington, 1993; Faleyimu and Oso, 2012). There is a growing scientific consensus about the impending loss of tropical species as some of these species may not be available to future generations of natural product drug discovery scientists (Gurib-Fakim, 2006). Plants of the tropical rainforests especially in Malaysia serve as a potential source of pharmaceutical leads due to the high chemical diversity. Hence, toxicity studies play an important role in the identification and isolation of pharmaceutical leads from medicinal plants.

Although *Euphorbia hirta* (*E. hirta*) has been used for generations as a medicinal herb, however little is known of the toxicological potential of the herb. Based on their long-term use by humans, one might expect *E. hirta* used in traditional medicine to have low toxicity. However, recent research have revealed that many plants used as food or in traditional medicine showed toxic effects in *in vitro* assays (Cardoso *et al.*, 2006; Mohd-Fuat *et al.*, 2007). This raises concern about the potential toxic hazards resulting from the short-term and long-term use of *E. hirta*. Therefore, evaluating the toxicological effects of *E. hirta* extract intended to be used in humans is a crucial part of its assessment for potential hazards. Regarding drug discovery and development, there are different weights of interest of all
concerned groups, which need to be taken into consideration (Olejniczak et al., 2001). The general public, patients and consumers are mostly interested in the fast access to safe and efficient medicines, as well as in animal welfare. Health authorities are obliged to make sure that laws and regulations are followed, i.e., both regulatory laws on medicines and on animal protection.

Moreover, the pharmaceutical industry plans to produce safe and ethical medicine in the most economic way. The different interests of the public, the pharmaceutical industry and health authorities may lead to potential conflicts. Therefore, the ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use), the common regulatory initiative of the EU, USA and Japan has addressed these topics in their mission and goals, which are: to provide and assure safe and ethical medicines; to maintain regulatory compliance; to achieve fast development and market authorization; to economize costs and to consider animal protection (ICH, 2007). In light of the given situation of therapeutic agents development and because of the above described interests, new approaches are progressing in different phases of drug development that allow for more efficient, yet safe procedures. One possible way to economize time and costs, as well as to address animal protection, is to introduce alternative methods into non-clinical safety testing. Currently, animal tests are mandatory for the evaluation of acute toxicity of chemicals and new drugs. The replacement of the in vivo tests by alternative in vitro assays would offer the opportunity to screen and assess numerous plants extract at the same time, to predict acute oral toxicity and thus accelerate drug development processes. Furthermore, the substitution of in vivo tests by in vitro methods shows a proactive pursuit of ethical
and animal welfare issues. There is little toxicological data available on _E. hirta_ although the plant has been used as herbal medicine since ancient time. Hence, the current study was designed to compare the _in vivo_ and _in vitro_ toxicity of _E. hirta_ extract besides evaluating its potential as anticancer agents and its mechanism of actions. The conflict between _in vitro_ and _in vivo_ studies persists as the results obtained from _in vitro_ studies are often not directly interpretable in the context of potential _in vivo_ exposures (Yoon _et al._, 2012). _In vitro_ data from cell-based assays should be viewed as indicators of potential toxicity, but not as absolute markers. On the other hand, _in vivo_ data from animal studies are more indicative of toxicity and may be considered to be safety markers (WHO, 2000).

Cancer is a growing health problem around the world characterised by uncontrolled cell growth. Breast cancer is the one of the most common cancer in females. Global breast cancer case has increased from 1.38 million women in 2008 to more than 1.6 million in 2010 (Ferlay _et al._, 2012). There were 3242 female breast cancer cases diagnosed in 2007, accounted for 18.1% of all cancer cases reported and 32.1% of all female cases (Zainal and Nor Saleha, 2011). It is estimated over 60% of anticancer drugs available in the market are of natural origin and majority of these compounds are obtained from higher plants (Newmann _et al._, 2003). The development of anticancer drugs, especially cytotoxic agents from medicinal plants, differs significantly from the drug development process for any other indication. Major research efforts are aimed at discovery of molecular targets that are specific for cancer cells, development of agents that are toxic to cancer cells, and at devising their synergistic combinations. Hence, the identification toxicity of medicinal plants may contributes for the identification of medicinal plants that are selectively induces
cytotoxicity in cancer cells but not in normal cells, which is an unusual property that is not shared by conventional chemotherapeutic agents (Blagosklonny and Pardee, 2001; Li et al., 2003). The development of anticancer drugs from natural sources requires toxicity information on the constituent of interest. It should be emphasized that toxic effects of the anticancer agent on the host cells must be considered, as a substance may exhibit an apparent anticancer activity by virtue of its toxic effect on the cells. Therefore, in this study besides various toxicity evaluation of *E. hirta* extract, the anticancer potential of this plant on cancer cells was also evaluated to develop therapeutic agents which selectively toxic (toxicity to cancer cells but not to normal cells) on cancer cells.

**1.2 Research objectives**

The current study was undertaken with the following objectives:

1. To standardize the methanolic extract of *E. hirta*

2. To determine the *in vitro* cytotoxicity of methanolic extract of *E. hirta* on several cell lines and *Artemia salina*

3. To determine the mode and mechanism of cell death in MCF-7 cells treated with methanolic extract of *E. hirta*

4. To determine the genotoxicity of methanolic extract of *E. hirta*

5. To evaluate *in vivo* acute and sub-chronic oral toxicity of *E. hirta* extract administration in albino rats

6. To identify cytotoxic fraction/compound (s) from *E. hirta*
CHAPTER 2.0: LITERATURE REVIEW

2.1 Pharmaceuticals from plants

2.1.1 Background of herbal medicine in Malaysia

From prehistoric times, plants have been a valuable source of natural products for treatment of various diseases. This plant-based, traditional medicine system continues to play an essential role in health care, with about 80% of the world’s population relying mainly on traditional medicines for their primary modality of health care (Farnsworth et al., 1985; Jyothi et al., 2011).

Malaysia is among the world’s top 12 rich biodiversity countries where Ayurveda, Siddha, traditional Chinese, traditional Malay, Unani and other traditional systems of medicine are commonly practised. Therefore, Malaysia is to become a significant global player given that the global trade of herbal products, which amounted to RM777 billion in 2006 and is projected to triple by 2020 (Anonymous, 2011). Malaysia’s herbal industry has been identified as one of the agriculture Entry Point Projects (EPPs) under the National Key Economic Areas (NKEAs) in the Economic Transformation Programme (ETP). Several popular Malaysian herbs have been identified as the focus, including *Eurycoma longifolia* (Tongkat Ali), *Labisia pumila* (Kacip Fatimah), *Orthosiphon stamineus* (Misai Kucing), *Andrographis paniculata* (Hempedu Bumi) and *Phyllanthus niruri* (Dukung Anak) (Anonymous, 2011).

Herbal medicine or phytomedicine refers to the use of a plant's seeds, berries, roots, leaves, bark or flowers for medicinal purposes. Historically, herbal drugs were used as tinctures, poultices, powders and teas followed by formulations, and lastly as
pure compounds. There are 119 pure chemical compounds extracted from higher plants used in medicine and 74% of these compounds came from folklore claims (Gurib-Fakim, 2006). WHO recognizes herbal medicines as valuable resources and states it is necessary to develop a systematic inventory of medicinal plants to introduce regulatory measures, apply good manufacturing practices and to include herbal medicines in the conventional pharmacopoeia of each nation (WHO, 1998a).

Well-known examples of plant-derived prescription drugs include the antimalarial drug quinine obtained from the bark of Cinchona officinalis; the analgesics, codeine and morphine from Papaver somniferum; the antihypertensive reserpine from Rauwolfia serpentina; and the cardiac glycoside, digoxin, from Digitalis purpurea (Cragg and Newman, 1999). Initially, quinine from cinchona bark was used to manage the symptoms of malaria long before the disease was identified and the raw ingredients of a common aspirin tablet have been a popular painkiller for far longer than we have had the access to tablet-making machinery (Ansari and Inamdar, 2010).

Tropical rain forests continue to support a vast reservoir of potential drug from plant species due to their ability to synthesize various chemicals as defense agents against pests, diseases and predators. They are an excellent reservoir of medicines and chemical leads with which researchers can design and synthesize new drugs (Zakrzewski, 2002). The potential for finding more compounds is enormous as to date only less than 1% of tropical forest plant species have been tested for chemical compounds and medicinal value, yet at least 25% of all modern drugs originally came from rainforests (Rates, 2001). Due to the disappearance of tropical plant
species, there is a sense of urgency to increase screening efforts and investigate commercial potential of tropical plant chemicals.

2.1.2 Safety concern on the use of pharmaceutical from plants

Safety is a fundamental principle in the provision of herbal medicines and a critical component of quality control. Herbal medicines are generally considered as safe based on their long-standing use in various cultures. However, there were case reports of serious adverse effects after administration of herbal products. High profile issues such as adverse reactions associated with *Ephedra* and *Aristolochia* have shown that herbal medicine can produce toxicity after consumption in humans (Jordan *et al.*, 2010). A number of other plant-derived agents were entered into clinical trials and were terminated due to the lack of efficacy or unacceptable toxicity. Some examples are acronycine, bruceantin, maytansine and thalicarpine (Cragg *et al.*, 1993). Some adverse effects reported in association with herbal products are attributable to quality issue. Toxicity associated with herbal medicines may result from misidentification of plant species, contamination with toxic metals and pesticide, adulteration with pharmacologically active synthetic compounds and herb-drug interactions (Ernst, 2004; Van Breemen *et al.*, 2008).

This issue has led to the regulation of traditional medicines through legally enforced product registration in Malaysia in January 1992. However, herbal medicines are not rigorously regulated by the Drug Control Authority (DCA) of Malaysia. The evaluation of the quality and safety of herbal medicines by the DCA is limited to control on the content of specified adulterants and contaminants such as heavy metals and micro-organisms (Aziz, 2009). Given that herbal medicines are often assumed as being harmless, the public may be at risk of adverse effects from
the use of herbal medicines. The scientific evaluation of safety and efficacy of herbal products and medicinal preparation is thus of vital importance from both medicinal and economic perspectives.

2.2 Euphorbia

*Euphorbia* is a genus of flowering plants belonging to the family Euphorbiaceae, comprises about 300 genera and 5,000 species, common to tropical countries (Figure 2.1). The genus *Euphorbia* is the largest in spurge family, comprising more than 2000 species (Aslam et al., 2014). It is characterized by the presence of white milky latex which is toxic to a certain extent (Kumar et al., 2010).

2.2.1 Euphorbia hirta L.

2.2.1.1 Botanical description

*E. hirta* is a small annual, branched herb prostrate to ascending with branches reaching 70 cm in height (Figure 2.2). It is reddish or purplish in color, with abundant latex and is covered with short hairs. Its leaves are opposite, distichous and simple (not lobed or divided). The leaf blades are lanceolate-oblong, long elliptic or ovate-lanceolate. The inflorescence of *E. hirta* has a terminal or axillary cluster of flowers, called a ‘cyathium’, with several cyathia densely clustered into a cyme (Figure 2.3). The flowers of *E. hirta* are unisexual; the male flowers are sessile, the bracteoles are linear, fringed, the perianth is absent and possesses one stamen, whereas the female flowers have short pedicel, the perianth is rimmed, the ovary is superior, covered with short hairs, three-celled, possesses three styles, minute and the apex is two-fid. The fruit of *E. hirta* is exerted, acutely three-lobed, base truncate, covered in short hairs and three-seeded. The seeds are oblong, four-sided
prismatic, slightly wrinkled, pinkish brown and caruncle absent. Flowering duration of individual plant is usually throughout the year. *E. hirta* often grows in cultivated areas in lowland, paddy fields, gardens, roadsides and waste places. They prefer dry condition, from sea-level up to 2000 m altitude. *E. hirta* has many synonyms in different countries. The common names for *E. hirta* are snakeweed, asthmaweed, hairy spurge and milkweed. In Malaysia, it is called ambin jantan, kelusan, gelang susu or keremak susu (Huang et al., 2012). Figure 2.1 shows the taxonomic classification of *E. hirta* plant.

2.2.1.2 Origin and geographical distribution

*E. hirta* is native to Central America and a very common weed of the tropics and subtropics; it occurs throughout tropical Africa and also in South Africa (PROSEA, 2014)
Figure 2.1: Taxonomic classification of *E. hirta* (Mamun-Or-Rashid *et al.*, 2013)
Figure 2.2: Euphorbia hirta plant
Figure 2.3: *E. hirta* plant (1: plant habit; 2: young cyathium; 3: mature cyathium; 4: seed) (PROSEA, 2014)
2.2.1.3 Phytochemistry

Phytochemical analysis of *E. hirta* showed the presence of reducing sugar, alkaloids, flavonoids, sterols, tannins and triterpenes in the whole plant. Sterols isolated from *E. hirta* are cycloartenol, 24- methylene-cycloartenol, β-sitosterol, euphorbol hexacozonate, 1-hexacosanol, tinyaloxin, campesterol and stigmasterol (Shih and Cherng, 2012). *E. hirta* contains three hydrolysable tannins, namely, dimeric hydrolysable tannin, euphorbin E and the dimeric dehydroellagitannins, euphorbin A and euphorbin B (Yoshida *et al*., 1990). Polyphenols from the leaves of *E. hirta* were also isolated by using physicochemical and spectroscopic methods: gallic acid, 2,4, 6-tri-O-galloyl-D-glucose, quinic acid ester, 1,2,3,4, 6-penta-O-galloyl- β-D-glucose and 3,4-di-O-galloylquinic acid (Chen, 1991). The triterpenes β-amyrin, 24-methylencycloartenol and β-sitosterol have been identified from *E. hirta* (Martinez *et al*., 1999). Flavonol glycosides were isolated from methanolic extract of *E. hirta* and chemically characterized as afzelin, quercitrin, and myricitrin (Liu *et al*., 2007). The chemical structure of 2,4, 6-tri-O-galloyl-D-glucose, β-sitosterol, myricitrin, gallic acid and quercitrin found in *E. hirta* are showed in Figure 2.4.
**Figure 2.4:** Chemical structure of some known compounds found in *E. hirta*
(Source: http://www.chemspider.com/Chemical-Structure)
2.2.1.4 Pharmacological activities

_E. hirta_ exhibited several pharmacological activities as reported in literature. The antibacterial activity of _E. hirta_ has been comprehensively investigated and proven. The ethanolic extract of _E. hirta_ inhibited the growth of the _Escherichia coli_, _Staphylococcus aureus_, _Pseudomonas aeruginosa_ and _Bacillus subtilis_ (Ogbulie _et al._, 2007). Aqueous and chloroform leaf extracts of _E. hirta_ possess an antibacterial activity against _Klebsiella pneumonia_ (Suresh _et al._, 2008).

The antidiarrheal effect of the herb decoction was studied in mice. The lyophilised decoction of _E. hirta_ was found to possess antidiarrheal activity induced by castor oil, arachidonic acid and prostaglandin E2 (Galvez _et al._, 1993a). Quercitrin isolated from _E. hirta_ showed an antidiarrheal activity at a dose of 50 mg/kg against castor oil and prostaglandin E2-induced diarrhea in mice (Galvez _et al._, 1993b).

The antioxidant activity of _E. hirta_ was comparable with that of ascorbic acid and found to be dose dependent (Basma _et al._, 2011). The aqueous extract of _E. hirta_ showed an antioxidant effect and a free radical scavenging activity in various _in vitro_ models like total antioxidant and total ferric reducing power determination, assay for free radical-scavenging activity using ABTS, DPPH and hydroxyl radical scavenging assays. It showed maximum antioxidants and free radical scavenging activities at 0.25 mg/mL (Sharma _et al._, 2007).

_E. hirta_ was reported to possess antimalarial activity. The bioassay-guided fractionation of methanol extracts of the aerial parts of _E. hirta_ resulted in isolation of flavonol glycosides afzelin, quercetrin and myricitrin. The compounds showed...
inhibition of the proliferation of *Plasmodium falciparum* with IC\textsubscript{50} values of 1.1, 4.1, 5.4 µg/mL, respectively. Furthermore, they showed little cytotoxic activity against human epidermoid carcinoma KB3-1 cells (Liu *et al.*, 2007).

Antiinflammatory effects of *E. hirta* were exhibited in 12-o-tetradecanoyl phorbol acetate-induced ear inflammation in mice whereby the result showed a dose-dependent effect (Martinez *et al.*, 1999; Lanhers *et al.*, 1991). In some recent studies, *E. hirta* produced a remarkable antiinflammatory effect via its active component of beta-amyrin and showed a dose-related inhibition against LPS-induced NO production (Camuesco *et al.*, 2004; Shih *et al.*, 2010).

*E. hirta* was found to have an antiasthmatic activity due to the relaxation effect on the bronchial tubes and a depressant action on respiration (Kumar *et al.*, 2010). *E. hirta* reduced asthma attack has been shown as effective as corticosteroid did in the BALB/c asthmatic mouse mode (Ekpo and Pretorius, 2008). The possible active component of *E. hirta* is thought to be quercitrin. *E. hirta* ethanol extract significantly prevented eosinophil accumulation and eosinophil peroxidase activity and reduced the protein content in bronchoalveolar lavage fluid in a 'mild' model of asthma (Singh *et al.*, 2006).

### 2.2.1.5 Ethnopharmacology

*E. hirta* plays a very important role in traditional use due to its wide range of biological and pharmacological properties. The plant part used are the whole plant, latex, aerial part, root and leaf. Different formulations are used, including crude drug, decoction, infusion, lotion and powders. The latex and fluid extract of the tincture are used to treat gastrointestinal disorders (diarrhea, dysentery, intestinal
parasitosis), bronchial and respiratory diseases (asthma, bronchitis, hav fever) (Kumar et al., 2010). The decoction of the root is used to alleviate vomiting. Decoction of dry herbs is used for skin diseases. Root decoction is used for snake bites, sores, wounds, boils and is beneficial for nursing mothers with deficient milk. The entire plant is prescribed as an antidote; it is considered hemostatic, sedative and narcotic. In Australia, the most common use of *E. hirta* is to treat hypertension, asthma, edema and pectoral complaints. In the Philippines, leaves are mixed with datura metel leaves and flowers in the preparation of "asthma-cigarettes" (Huang et al., 2012).

### 2.2.1.6 Plant derived anticancer agents

Plants have enormous contribution to modern medicine with the origin of numerous drugs in use today are derived from plants. Most of these plant-derived drugs were originally discovered through the study of herbal cures and folk knowledge of traditional people. Some of these could not be synthesised economically and are still obtained from wild or cultivated plants despite the enormous advancement in synthetic chemistry. Natural product secondary metabolites from plants and microbes in particular play a very important role in the amelioration of cancer. In the field of anticancer activity, a correlation between biological activity and plants used in folklore has been validated (Farnsworth and Kaas, 1981). More than 60% of all cancer drugs are of natural origin and a majority of these compounds are obtained from higher plants (Newmann et al., 2003).

In the 1970s, one of the significant breakthroughs in the field of anti-cancer drugs comes from the Madagascan Periwinkle. The Periwinkle has a long history of treating a wide variety of diseases and has also been used for centuries against
diabetes. This traditional use as a cure for diabetes resulted in preliminary laboratory investigations. Laboratory animals developed significantly low counts of white blood cells leaving them defenseless against infections caused by bacteria. The result showed that one or more of the Periwinkle alkaloids might slow or halt white blood cell production and this is probably the mechanism that evolved in nature to discourage herbivorous predators from eating the Madagascan Periwinkle. Hence, further bioassay-guided isolation of the plant led to the characterization of the active complex alkaloidal compounds namely vincristine and vinblastine. The level of vincristine in the plant is extremely low (0.0002%) and thus making it a very expensive antitumour agent. They have been proven to be effective agents against childhood leukaemia, breast cancer and Hodgkin’s disease. Vincristine and vinblastine exert their anticancer properties by inhibiting mitosis by binding to tubulin, thus preventing the cell from making spindles it needs to be able to move its chromosomes around as it divides (Gurib-Fakim, 2006).

Other examples of plant-derived anticancer drug are etoposide and teniposide, which are semisynthetic derivatives of the natural product epipodophyllotoxin. Epipodophyllotoxin is an isomer of podophyllotoxin that was isolated as the active antitumor agent from the roots of various species of the genus Podophyllum. These plants have a long history of medicinal use by early American and Asian cultures, including the treatment of skin cancers and warts. Etoposide is now marketed as Vepesid for small cell lung cancer, testicular cancer and lymphomas while Teniposide is used in treating brain tumours (Cragg and Newman, 1999). Recent plant-derived anticancer drug are homoharringtonine isolated from the Chinese tree, Cephalotaxus harringtonia (Cephalotaxaceae) and elliptinium, a derivative of
ellipticine isolated from species of plant family Apocynaceae including *Bleekeria vitensis*, a Fijian medicinal plant with reputed anti-cancer properties. Combretastatin isolated from the bark of the South African tree *Combretum caffrum* Kuntze is active against colon, lung and leukemia cancers. It is considered to be the most cytotoxic phytomolecule isolated so far (Unnati et al., 2013).

### 2.3 Cell death

Cell death is a general biological phenomenon, which continues throughout the lives of organisms and is important to maintain normal cellular homeostasis. Cell deaths during embryonic development are vital for successful organogenesis and the crafting of complex multicellular tissues (Nika and Stanley, 2004). Defects in apoptotic cell death regulation may lead to many diseases. Acquired Immunodeficiency Syndrome (AIDS), neurodegenerative disorders, insulin-dependent diabetes, hepatitis C infection, myocardial infarct and atherosclerosis are examples of disorders with inappropriate apoptosis or increased rate of apoptosis, whereas autoimmune diseases and cancer are disorders with decreased rate of apoptosis (Ulukaya et al., 2011).

During cell death, activation of distinct biochemical cascades follows and manifest with different morphological features. Cell death can occur by either of two distinct mechanisms, namely, apoptosis or necrosis. Apoptosis or programmed cell death is the physiological process by which unwanted or useless cells are eliminated during development and other normal biological processes. The biochemical and morphological events that lead to apoptosis usually have a highly regulated series of events. Necrosis or accidental cell death is a pathological process
in response to trauma generated by external factors or overwhelming cellular injury (Figure 2.5) (Fa’timah and Pedro, 2010).

2.3.1 Apoptosis and necrosis

The term ‘apoptosis’ was first coined by Kerr et al. (1972) to describe the specific morphological features leading to the programmed cell death. Apoptosis is of Greek origin, having the meaning "falling off or dropping off", in analogy to leaves falling off trees or petals dropping off flowers (Sankari et al., 2012). This analogy emphasizes that the death of living matter is an integral and necessary part of the life cycle of organisms.

Apoptosis is a form of cell death characterized by cell shrinkage, membrane blebbing, chromatin condensation and looses contact to its neighbouring cells. Apoptotic cell is fragmented into compact membrane-enclosed structures, called 'apoptotic bodies' which contain cytosol, the condensed chromatin and organelles. Apoptosis is an active process as the apoptotic bodies are engulfed by macrophages and thus are removed from the tissue without causing an inflammatory response. These morphological changes are a result of characteristic molecular and biochemical events leading to the activation of proteolytic enzymes which eventually mediate the cleavage of DNA into oligonucleosomal and cleavage of a multitude of specific protein substrates which usually determine the integrity and shape of the cytoplasm or organelles (Saraste and Pulkki, 2000).

The term necrosis was originally used to define all types of cell death until Kerr (1971); Kerr et al. (1972) introduced the concept of apoptosis. Necrosis is of Greek origin, having the meaning "corpse" (Zong and Thompson, 2006). For a long
time, necrosis has been considered an accidental and uncontrolled form of cell death lacking underlying signaling events. Morphologically, necrosis is characterized by cytoplasmic and organelle swelling, followed by the loss of cell membrane integrity and loss of intracellular contents (Duprez et al., 2009). During necrosis, the intracellular contents are released uncontrolled into the cell's environment which results in damage of surrounding cells and a strong inflammatory reaction in the corresponding tissue (Leist and Jaattela, 2001).
Figure 2.5: Types of cell death [Source: Walker et al., (1988)].
2.3.2 Mechanism of apoptotic and necrotic cell death

2.3.2.1 Apoptosis pathways

Occurrence of apoptosis is controlled by a number of complex proteins, which are activated by various triggers and arranged in sequential signaling modules. There are two main pathways that lead to apoptosis. The first, referred to as the intrinsic or mitochondrial pathway that when stimulated leads to the release of cytochrome-c from the mitochondria and activation of the death signal. The second pathway is the extrinsic or cytoplasmic pathway, is triggered through the Fas death receptor, a member of the tumor necrosis factor (TNF) receptor superfamily. Both pathways converge to a final common pathway involving the activation of caspases that cleave regulatory and structural molecules resulting in the death of the cell (Ghobrial et al., 2005).

2.3.2.1.a Intrinsic pathway

In the intrinsic or mitochondrial pathway of apoptosis, caspase activation is closely linked to permeabilization of the outer mitochondrial membrane (Green and Kroemer, 2004). This permeabilization is regulated by proteins from the Bcl-2 family. The Bcl-2 family includes proapoptotic members such as Bax, Bak, Bad, Bcl-Xs, Bid, Bik, Bim, and Hrk, and antiapoptotic members such Bcl-2, Bcl-XL, Bcl-W, Bfl-1, and Mcl-1. Antiapoptotic Bcl-2 members act as suppressors of apoptosis by blocking the release of cytochrome-c, whereas proapoptotic members act as promoters (Reed, 1997).
Upon triggered by a death signal, proapoptotic proteins undergo posttranslational modifications that include dephosphorylation and cleavage resulting in their activation and translocation to the mitochondria leading to apoptosis. The activation of Bcl-2 members such as Bax and Bak may cause an increase of mitochondrial membrane permeability, leading to the release of cytochrome-c and second mitochondria-derived activator of caspase (SMAC) or inhibitor of apoptosis proteins (IAPs) into cytosol. The release of cytochrome c then binds and activate with Apaf-1, as well as procaspase-9, forming an “apoptosome”. Activation of caspase-9 then activates caspase-3, which subsequently activates the rest of the downstream caspases and leads to apoptosis (Ghobrial et al., 2005).

2.3.2.1.b Extrinsic pathway

The extrinsic pathway or death receptor pathway initiates apoptosis via transmembrane receptor-mediated interactions. These involve death receptors that are members of the TNF receptor gene superfamily (Susan, 2007). These proteins comprise death receptors, the membrane-bound Fas ligand, the Fas complexes, the Fas-associated death domain, and caspases 8 and 10 (Ghobrial et al., 2005). Activation of the extrinsic pathway is initiated with the ligation of cell surface receptors called death receptors (DRs). Fas is a member of the tumor necrosis factor receptor superfamily, also known as Apo-1 or CD95. Other TNF receptors include TNF R1, DR3 (Apo 2), DR4 (TRAIL R1), DR5 (TRAIL R2), and DR6 (Zapata et al., 2001).

Following a death stimulus, the FasL interacts with the inactive Fas complexes and forms the death-inducing signaling complex which contains the adaptor protein Fas-associated death domain protein and caspases 8 and 10. This